Yu Xin, Li Zheng
Department of Dermatology, Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China.
Oncol Res. 2014;22(5-6):333-8. doi: 10.3727/096504015X14410238486568.
BLID (BH3-like motif containing, cell death inducer), also known as breast cancer cell 2 (BRCC2), was first reported in the human breast cancer cell line in 2004. BLID is a BH3-like motif containing apoptotic member of the Bcl-2 family. Recently, the BLID tumor-suppressor roles have been fully established. Several studies have found that BLID is frequently downregulated in many human cancers and the downregulation is often associated with tumor progression. Multivariate analysis indicated that BLID is an independent prognostic factor for overall survival and distant metastasis-free survival. Moreover, BLID can inhibit breast cancer cell growth and metastasis and promote apoptosis. BLID can regulate the expression of various tumor-related genes and proteins, such as AKT and MMP. In this review, we provide an overview of current knowledge concerning the role of BLID in tumor development and progression. To our knowledge, this is the first review about the role of this novel tumor-suppressor gene in tumor development and progression.
含BH3样基序的细胞死亡诱导因子（BLID），也被称为乳腺癌细胞2（BRCC2），于2004年首次在人乳腺癌细胞系中被报道。BLID是Bcl-2家族中一个含BH3样基序的凋亡成员。最近，BLID的肿瘤抑制作用已得到充分证实。多项研究发现，BLID在许多人类癌症中经常下调，且这种下调通常与肿瘤进展相关。多变量分析表明，BLID是总生存期和无远处转移生存期的独立预后因素。此外，BLID可抑制乳腺癌细胞的生长和转移并促进细胞凋亡。BLID可调节多种肿瘤相关基因和蛋白质的表达，如AKT和MMP。在本综述中，我们概述了目前关于BLID在肿瘤发生和进展中作用的相关知识。据我们所知，这是关于这个新型肿瘤抑制基因在肿瘤发生和进展中作用的首次综述。
